Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

Aspira Women's Health Inc.

Aspira Women's Health provides innovative testing solutions for gynecologic care, utilizing a data-driven approach to empower patients and healthcare providers.

Aspira Women's Health

Aspira Women&#39;s Health | 5,551 followers on LinkedIn. Globally transforming women&#39;s health, starting with ovarian cancer. | Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. 

Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite℠, which includes OvaWatch℠, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time.

Board Director, SCA Pharma (PE-Backed) | Board Director, Aspira Women’s Healthcare (NASDAQ-listed) | Former Chair, Parkland Hospital | Committee…

Winfred Parnell

Julie Carrillo

IT Director, Consultant Chief Technical Officer

Luis de la Guardia

Business Development | Laboratory Diagnostics Expert

Matt Ramey

Our expanded collaboration with Aspira Women's Health to co-market Aspira’s complete OvaSuite portfolio, including OvaWatch® and Ova1Plus®, is a testimony of our continuous commitment to offering top-tier testing to aid BioReference® women’s healthcare provider clients in New York and New Jersey in managing patients and help improve patient outcomes. Learn more about this exciting collaboration here: https://lnkd.in/e5hXnF62

BioReference

🤝 New partnerships grab headlines in ovarian cancer, infertility & menopause! 𝐒𝐈𝐒 𝐖𝐞𝐞𝐤𝐥𝐲 𝐒𝐜𝐨𝐨𝐩 🍦 𝐄𝐝𝐢𝐭𝐢𝐨𝐧 𝟑𝟐, below👇 🏠 iGii and Prymexa agree multi-million deal to diagnose early signs of menopause with at-home toolkit | Sara Pardoe , Jean-Christophe Granier , David Atkinson | https://lnkd.in/eve2BSfd 💫 Aspira Women's Health expands partnership with BioReference to include OvaWatch®, a non-invasive blood test assessing the risk of ovarian cancer | Nicole Sandford , Ellen Beausang | https://lnkd.in/e7GnNDMA 🔬 Parallel Fluidics raises $7M to advance microfluidic tech for IVF and life sciences | Joshua G. , Lionel Matthys , Jonathan Bronson | https://lnkd.in/ehSHvwGV 👶 Femasys Inc. announce partnership with Boston IVF to expand its infertility product FemaSeed across the US | Kathy Lee-Sepsick , David Stern | https://lnkd.in/eFmEUNHD 🦴️ Naitive and Parvizi Surgical Innovation partner to advance osteoporosis detection | Javad Parvizi , Wael Barsoum , Will Briggs | https://lnkd.in/eps8A_x3 🙋♀️ Lindus Health introduces "All-in-One Women’s Health CRO", offering bespoke clinical trials for women’s health products | Emma Ogburn | https://lnkd.in/e2KHj6zs 🎤 SiS: Women's Health adds several expert speakers to their 2025 New York event panels | Annie Theriault , Shelly Lanning , Brittney Gavini | https://lnkd.in/g6aaVRr2 ⏱ TIME release article stating, "Women Are Still Under-Represented in Medical Research," with menopause & endometriosis most overlooked | Primavera Alessandra Spagnolo , | https://lnkd.in/dQ53qAkD For everything Women's Health & FemTech, follow 👉 SiS: Women's Health #WomensHealth #FemTech #news Photo: iGii 's menopause at-home toolkit

SiS: Women's Health

Exciting news from Aspira Women’s Health! We are proud to announce the expansion of our co-marketing and distribution collaboration with BioReference to include OvaWatch®. This partnership enhances our commitment to providing comprehensive ovarian cancer risk assessment solutions to more women nationwide. By teaming up with BioReference, we’re poised to reach even more healthcare providers and empower women with proactive, insightful tools for early intervention in their ovarian health journey. Learn more about how this collaboration marks a significant step forward in our mission to transform women’s health in our latest press release: https://lnkd.in/e5hXnF62 #AspiraWomensHealth #OvaWatch #WomensHealth #OvarianCancerAwareness #HealthcareInnovation #Partnerships

Women’s Health . . or the Health of Women? Can’t wait to dive into this discussion with #trailblazers Julie Gerberding , Diana W. Bianchi M.D. , Sandy Milligan, MD JD , and Elizabeth Garner at the upcoming The Galien Foundation forum. From #publichealth to clinical medicine, basic science #research to policy formulation, and then #innovation to #impact , these #trailblazers have not just moved the needle, they’ve shifted the tectonic plates of our global health ecosystem to create enabling environments for more inquiry, investment and interventions in this space. It will also be a treat to celebrate all of the #PrixGalien award winners, as well as Kenneth C. Frazier, in his role as Chair of the 2024 USA Awards Committee. I can’t wait!

Mary-Ann Etiebet, MD, MBA

The National Ovarian Cancer Coalition is cheering on our TEAM TEAL runners as they gear up to hit the streets of NYC this Sunday, November 3, 2024, and bring a wave of teal to the "Big Apple"! With an impressive team of 50 runners raising over $281,000 to support NOCC's mission, they’re making a powerful impact with every mile. Together, they’re showing that with action, there is HOPE! Make sure to follow our TEAM TEAL social media pages for updates all weekend at https://bit.ly/3UxSL4u and https://bit.ly/3Uyn6jq

National Ovarian Cancer Coalition

Aspira Women’s Health has been recognized by U.S. Senator Chris Murphy’s office as “Innovator of the Month!” This honor underscores our dedication and tireless commitment to transforming women’s health diagnostics. “For decades, underinvestment in women’s health has meant that women and girls simply aren’t getting access to the treatments and care they deserve. I’m proud to see Aspira’s cutting-edge biomedical research positioning Connecticut as a leader in women’s healthcare and improving lives through earlier risk assessment, more accurate diagnoses, and innovative, personalized care,” said Murphy. Read the full press release and learn more about this recognition here: https://bit.ly/4elKwj0 #InnovatorOfTheMonth #WomensHealth #AspiraWomensHealth #OvarianCancerAwareness #OvarianCancer #EndoAwareness #Endometriosis

Aspira Women’s Health will announce our Third Quarter Earnings Results on Thursday, November 14, 2024, at 8:30 a.m. ET. Join our leadership team as they discuss financial results and provide a corporate update. Make sure to register! If you can’t tune in live, you can catch the replay on our website’s Events & Presentations page. For more details and to register, check out the full announcement here: https://lnkd.in/eMD5jqhP #AspiraWomensHealth #EarningsCall #HealthcareInnovation #WomensHealth #EarningsResults

Thank you to everyone who joined us today at our Shelton, CT, headquarters to celebrate Aspira Women’s Health’s $10M Advanced Research Projects Agency for Health (ARPA-H) award! Also in attendance, alongside U.S. Representative Rosa DeLauro, Dr. Elise Courtois of EndoRISE , State Representative Jillian Gilchrest, and Shantana Hazel , Founder of the Sister Girl Foundation, was Ovie, our ovarian mascot! Together, we recognized this milestone in advancing AI-powered gynecologic diagnostics and the invaluable contributions of our team and partners in this impactful mission. Learn more about how we plan to transform endometriosis detection in our recent announcement: https://lnkd.in/eJv9Tff6 #AspiraWomensHealth #WomensHealth #SprintforWomensHealth #Endometriosis #Endo #EndoResearch #EndoAwareness

"At 17, my life was about to change dramatically" - Tiffany Tiffany found out she had ovarian cancer when she was still a teenager, after months of doctors dismissing her symptoms. Now 30, she reflects on what it was like to be a young person coping with a cancer diagnosis. Read Tiffany's story - https://lnkd.in/eGiCvXee

Ovarian Cancer Action

The First Lady of the United States Dr. Jill Biden spoke on the #HLTHUSA Main Stage this morning about women’s health research. “It’s a problem that’s so simple—yet often ignored: women’s health is understudied and research is underfunded. As a result, too many of our medications, treatments, health products, and medical school textbooks are based on men. That’s why, if you ask any woman in America about her health care, she probably has a story to tell.” What a way to close out HLTH USA 2024 🫳🎤

NASDAQ:AWH

Aspira Women's Health

Last Close

0.86

12/11 19:36

Market Cap

14.69M

Beta: 2.93

Volume Today

41.67K

Avg: 243.20K

PE Ratio

−2.56

PFCF: −2.48